5 Best Biotech Stocks Under $10

Page 5 of 5

1. Kezar Life Sciences, Inc. (NASDAQ:KZR)

Share Price as of September 23: $8.02

Number of Hedge Fund Holders: 28

Kezar Life Sciences, Inc. (NASDAQ:KZR) is a clinical-stage biotechnology company involved in the research and development of novel small molecule therapeutics to treat immune-mediated diseases and cancer. The company’s flagship product is KZR-616, a phase-2 immunoproteasome inhibitor to treat lupus nephritis, dermatomyositis, and polymyositis, among other diseases.

On June 28, JonesTrading analyst Catherine Novack raised her price target on Kezar Life Sciences, Inc. (NASDAQ:KZR) to $20 from $17 and maintained a Buy rating on the shares.

On July 11, Kezar Life Sciences, Inc. (NASDAQ:KZR) disclosed that the company holds $307 million in cash, cash equivalents, and marketable securities as of June 30, 2022.

At the close of the second quarter of 2022, 28 hedge funds were long Kezar Life Sciences, Inc. (NASDAQ:KZR) and held stakes worth $231.6 million in the company. Of those, Suvretta Capital Management was the leading shareholder with stakes worth $36.49 million. The investment covers 1.38% of Aaron Cowen’s 13F portfolio.

You can also take a look at 10 Best Biotech Penny Stocks To Buy and 11 Best Pharma and Biotech Stocks to Buy.

Page 5 of 5